Compounds > dabigatran
Page last updated: 2024-09-05

dabigatran and transforming growth factor beta

dabigatran has been researched along with transforming growth factor beta in 3 studies

Compound Research Comparison

Studies
(dabigatran)		Trials
(dabigatran)		Recent Studies (post-2010)
(dabigatran)		Studies
(transforming growth factor beta)		Trials
(transforming growth factor beta)		Recent Studies (post-2010) (transforming growth factor beta)
3,8872613,49049,11956017,610

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's2 (66.67)2.80

Authors

AuthorsStudies
Anstee, QM; Dhar, A; Goldin, RD; Levene, AP; Sadiq, F; Thursz, MR1
Annaldas, S; Godugu, C; Saifi, MA1
Broncel, M; Gorzelak-Pabiś, P; Pawlos, A; Wojdan, K; Woźniak, E1

Other Studies

3 other study(ies) available for dabigatran and transforming growth factor beta

ArticleYear
Thrombin and factor Xa link the coagulation system with liver fibrosis.
    BMC gastroenterology, 2018, May-08, Volume: 18, Issue:1

    Topics: Actins; Animals; Antithrombins; Blood Coagulation; Cell Line; Cell Shape; Dabigatran; Disease Models, Animal; Factor Xa; Factor Xa Inhibitors; Gene Expression; Hepatic Stellate Cells; Humans; Hydroxyproline; Liver Cirrhosis; Male; Mice, Inbred C57BL; Procollagen; Receptor, PAR-1; Rivaroxaban; Thrombin; Transforming Growth Factor beta

2018
A direct thrombin inhibitor, dabigatran etexilate protects from renal fibrosis by inhibiting protease activated receptor-1.
    European journal of pharmacology, 2021, Feb-15, Volume: 893

    Topics: Animals; Antithrombins; Collagen Type I; Dabigatran; Disease Models, Animal; Epithelial-Mesenchymal Transition; Fibrosis; Kidney; Kidney Diseases; Male; Mice; Oxidative Stress; Receptor, PAR-1; Signal Transduction; Snail Family Transcription Factors; Transforming Growth Factor beta; Ureteral Obstruction

2021
Expression of anti and pro-inflammatory genes in human endothelial cells activated by 25-hydroxycholesterol: A comparison of rivaroxaban and dabigatran.
    Clinical and experimental pharmacology & physiology, 2022, Volume: 49, Issue:8

    Topics: Administration, Oral; Anticoagulants; Atherosclerosis; Atrial Fibrillation; Cytokines; Dabigatran; Endothelial Cells; Human Umbilical Vein Endothelial Cells; Humans; Hydroxycholesterols; Interleukin-18; Interleukin-23; Oxysterols; Rivaroxaban; RNA, Messenger; Transforming Growth Factor beta

2022